Artwork

Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

๐Ÿง  REBOOTing Beta-Blockers โ€“ No Gains โš–๏ธ After Modern MI ๐Ÿ’”

4:59
 
Share
 

Manage episode 503582562 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

๐Ÿšซ๐Ÿ’Š Should We Rethink Beta-Blockers Post-MI?

In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%).

๐Ÿ’ก A modern, pragmatic trial across 109 centers (Spain + Italy ๐Ÿ‡ช๐Ÿ‡ธ๐Ÿ‡ฎ๐Ÿ‡น) with 8438 patients โ€” shaking the foundation of our long-held post-MI practices.

๐Ÿ‘ฉโ€โš•๏ธ Signals of potential harm in women and STEMI subgroups raise questions, not answers.

๐Ÿ“‰ Should guidelines change? Or should practice just evolve?

#Cardiology #REBOOTTrial #BetaBlockers #NEJM #PrecisionMedicine #MedicalEducation #HeartAttack #LVEF #Guidelines #ClinicalTrials #InternalMedicine #EvidenceBasedMedicine #Revascularization

  continue reading

673 episodes

Artwork
iconShare
 
Manage episode 503582562 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

๐Ÿšซ๐Ÿ’Š Should We Rethink Beta-Blockers Post-MI?

In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%).

๐Ÿ’ก A modern, pragmatic trial across 109 centers (Spain + Italy ๐Ÿ‡ช๐Ÿ‡ธ๐Ÿ‡ฎ๐Ÿ‡น) with 8438 patients โ€” shaking the foundation of our long-held post-MI practices.

๐Ÿ‘ฉโ€โš•๏ธ Signals of potential harm in women and STEMI subgroups raise questions, not answers.

๐Ÿ“‰ Should guidelines change? Or should practice just evolve?

#Cardiology #REBOOTTrial #BetaBlockers #NEJM #PrecisionMedicine #MedicalEducation #HeartAttack #LVEF #Guidelines #ClinicalTrials #InternalMedicine #EvidenceBasedMedicine #Revascularization

  continue reading

673 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play